Heron Therapeutics Past Earnings Performance
Past criteria checks 0/6
Heron Therapeutics has been growing earnings at an average annual rate of 13.5%, while the Biotechs industry saw earnings growing at 19.1% annually. Revenues have been growing at an average rate of 0.05% per year.
Key information
13.5%
Earnings growth rate
21.9%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | 0.05% |
| Return on equity | n/a |
| Net Margin | -35.3% |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Recent updates
Investors Don't See Light At End Of Heron Therapeutics, Inc.'s (NASDAQ:HRTX) Tunnel And Push Stock Down 32%
Aug 08
Heron Therapeutics, Inc.'s (NASDAQ:HRTX) Share Price Boosted 31% But Its Business Prospects Need A Lift Too
May 30Heron Therapeutics: Zynrelef Potentially Eases Shareholder Pain
Apr 16Here's What Analysts Are Forecasting For Heron Therapeutics, Inc. (NASDAQ:HRTX) After Its Full-Year Results
Mar 15Heron Therapeutics, Inc. (NASDAQ:HRTX) Surges 27% Yet Its Low P/S Is No Reason For Excitement
Feb 15Heron Therapeutics, Inc. (NASDAQ:HRTX) Held Back By Insufficient Growth Even After Shares Climb 27%
Dec 22Heron wins FDA nod for post-operative agent to address nausea and vomiting
Sep 16Is Heron Therapeutics (NASDAQ:HRTX) A Risky Investment?
Aug 10Heron Therapeutics Q2 2022 Earnings Preview
Aug 08Heron Therapeutics proposes 34% cut in workforce as part of cost reduction plan
Jun 30Heron Therapeutics: Cash Is A Problem Again
Mar 31Heron Therapeutics: Changing Strategy After Disappointing Earnings
Mar 03Health Check: How Prudently Does Heron Therapeutics (NASDAQ:HRTX) Use Debt?
Jan 19Heron Therapeutics: Looking For Signs Of The Bottom
Oct 07Is Heron Therapeutics (NASDAQ:HRTX) Using Too Much Debt?
Oct 03Need To Know: Analysts Just Made A Substantial Cut To Their Heron Therapeutics, Inc. (NASDAQ:HRTX) Estimates
Aug 11Shareholders May Be A Bit More Conservative With Heron Therapeutics, Inc.'s (NASDAQ:HRTX) CEO Compensation For Now
Jun 11Heron Therapeutics files for 12.4M common stock offering from shareholder
May 28Revenue & Expenses Breakdown
How Heron Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 136 | -48 | 79 | -10 |
| 31 Mar 24 | 132 | -81 | 92 | 0 |
| 31 Dec 23 | 127 | -111 | 103 | 0 |
| 30 Sep 23 | 123 | -120 | 125 | 18 |
| 30 Jun 23 | 118 | -137 | 131 | 18 |
| 31 Mar 23 | 114 | -151 | 123 | 0 |
| 31 Dec 22 | 108 | -182 | 119 | 0 |
| 30 Sep 22 | 98 | -217 | 127 | 0 |
| 30 Jun 22 | 95 | -227 | 134 | 0 |
| 31 Mar 22 | 90 | -232 | 135 | 0 |
| 31 Dec 21 | 86 | -221 | 127 | 0 |
| 30 Sep 21 | 86 | -228 | 117 | 0 |
| 30 Jun 21 | 83 | -234 | 104 | 0 |
| 31 Mar 21 | 83 | -228 | 96 | 0 |
| 31 Dec 20 | 89 | -227 | 102 | 0 |
| 30 Sep 20 | 103 | -223 | 100 | 0 |
| 30 Jun 20 | 126 | -198 | 103 | 0 |
| 31 Mar 20 | 140 | -193 | 112 | 0 |
| 31 Dec 19 | 146 | -205 | 128 | 0 |
| 30 Sep 19 | 140 | -196 | 126 | 0 |
| 30 Jun 19 | 117 | -201 | 124 | 0 |
| 31 Mar 19 | 98 | -190 | 111 | 0 |
| 31 Dec 18 | 77 | -179 | 94 | 0 |
| 30 Sep 18 | 59 | -192 | 88 | 0 |
| 30 Jun 18 | 47 | -195 | 84 | 0 |
| 31 Mar 18 | 39 | -199 | 85 | 0 |
| 31 Dec 17 | 31 | -197 | 82 | 0 |
| 30 Sep 17 | 22 | -183 | 78 | 0 |
| 30 Jun 17 | 13 | -190 | 75 | 0 |
| 31 Mar 17 | 5 | -190 | 70 | 0 |
| 31 Dec 16 | 1 | -173 | 69 | 0 |
| 30 Sep 16 | 0 | -156 | 65 | 0 |
| 30 Jun 16 | 0 | -131 | 56 | 0 |
| 31 Mar 16 | 0 | -110 | 47 | 0 |
| 31 Dec 15 | 0 | -98 | 36 | 0 |
| 30 Sep 15 | 0 | -87 | 28 | 0 |
| 30 Jun 15 | 0 | -83 | 24 | 0 |
| 31 Mar 15 | 0 | -79 | 22 | 0 |
| 31 Dec 14 | 0 | -76 | 20 | 0 |
| 30 Sep 14 | 0 | -70 | 22 | 0 |
| 30 Jun 14 | 0 | -63 | 24 | 0 |
| 31 Mar 14 | 0 | -60 | 24 | 0 |
| 31 Dec 13 | 0 | -55 | 24 | 0 |
Quality Earnings: HRTX is currently unprofitable.
Growing Profit Margin: HRTX is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: HRTX is unprofitable, but has reduced losses over the past 5 years at a rate of 13.5% per year.
Accelerating Growth: Unable to compare HRTX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: HRTX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (0.5%).
Return on Equity
High ROE: HRTX's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.